PEREGRINE PHARMACEUTICALS Chart calendar Peregrine Pharmaceuticals
f341fed70537db1ddc0554b0651489d.PjulCRTVyj_HGD2BZwMeeosXMgHip6VJSjH7aeVNY3w.WArHRWSBslOuQgnXV3MpV-p2VXaJxu0OIn6DK7AaExdTdd0-XZG_ZqRdUg~3c731861342a6010189cd7121bbc1562
Upcoming events on Peregrine Pharmaceuticals
Past events on Peregrine Pharmaceuticals
| 25/06/2024 | Q4 2024 Earnings Release (Projected) |
| 16/05/2024 16:15 | BofA Securities Health Care Conference |
| 14/05/2024 21:35 | RBC Capital Markets Global Healthcare Conference |
| 29/04/2024 21:30 | Q3 2024 Earnings Call |
| 24/04/2024 22:25 | Q3 2024 Earnings Release |
| 07/12/2023 21:30 | Q2 2024 Earnings Call |
| 07/12/2023 21:05 | Q2 2024 Earnings Release |
| 23/10/2023 18:00 | Annual General Meeting |
| 03/10/2023 16:00 | RBC Capital Markets CDMO Conference |
| 07/09/2023 21:30 | Q1 2024 Earnings Call |
| 07/09/2023 21:05 | Q1 2024 Earnings Release |
| 21/06/2023 21:30 | Q4 2023 Earnings Call |
| 21/06/2023 21:07 | Q4 2023 Earnings Release |
| 17/05/2023 13:30 | RBC Global Healthcare Conference |
| 13/03/2023 20:30 | Q3 2023 Earnings Call |
| 13/03/2023 20:05 | Q3 2023 Earnings Release |
| 06/12/2022 21:30 | Interim 2023 Earnings Call |
| 06/12/2022 21:05 | Interim 2023 Earnings Release |
| 09/11/2022 20:50 | Credit Suisse Healthcare Conference |
| 18/10/2022 18:00 | Annual General Meeting |
Annual results
| Fiscal Period | Aprile | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 53,6 52,4 2.36% | 59,7 55,9 6.86% | 95,9 89,9 6.67% | 120 117 1.93% | 149 148 0.6% | 139 |
|
EBITDA Million USD | Released Forecast Spread | -2,88 0,00 - | -7,49 -7,76 3.38% | 15,7 14,3 9.92% | 30,4 27,2 12.06% | 21,7 20,3 6.72% | 1,81 |
|
EBIT Million USD | Released Forecast Spread | -5,62 -6,60 14.82% | -10,6 -13,5 21.34% | 12,2 10,9 12.16% | 15,4 18,2 -15.17% | 3,60 3,16 13.88% | -17,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -5,34 -11,3 52.74% | -10,5 -10,7 1.95% | 11,2 11,0 1.63% | 12,7 12,1 4.65% | 2,00 1,48 35.8% | -24,8 |
|
Net income Million USD | Released Forecast Spread | -8,90 -11,0 19.08% | -15,2 -14,5 -4.65% | 3,32 5,61 -40.89% | 128 12,1 955.26% | 0,56 0,78 -28.25% | -20,1 |
|
EPS USD | Released Forecast Spread | -0,16 -0,18 8.57% | -0,27 -0,33 19% | 0,06 0,09 -35.71% | 1,84 0,19 885.7% | 0,01 0,01 -20% | -0,32 |
| Announcement Date | 27/06/19 | 30/06/20 | 29/06/21 | 29/06/22 | 21/06/23 | - |
Quarterly results
| Fiscal Period | Aprile | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 31,5 25,3 24.51% | 31,2 29,0 7.83% | 36,7 33,4 9.71% | 34,8 32,1 8.41% | 38,0 36,3 4.68% | 39,8 38,9 2.32% | 37,7 36,1 4.55% | 25,4 33,2 -23.55% | 33,8 34,3 -1.39% | 42,1 | 40,7 | 34,3 | 40,7 | 48,2 |
|
EBITDA Million USD | Released Forecast Spread | 4,29 5,20 -17.38% | 5,89 4,40 33.8% | 6,19 5,92 4.56% | 1,89 5,24 -64.03% | 7,37 2,86 157.56% | 6,27 4,91 27.66% | 2,79 3,72 -24.88% | -5,97 1,77 -437.64% | -1,12 2,18 -151.22% | 5,54 | 4,29 | 0,93 | 4,45 | 8,01 |
|
EBIT Million USD | Released Forecast Spread | 3,27 3,00 8.98% | 1,07 2,03 -47.45% | 2,74 2,60 5.33% | -2,68 0,36 -853.93% | 2,72 -2,24 221.26% | 0,83 0,41 102.8% | -2,16 -1,61 -34.18% | -11,2 -4,40 -154.92% | -4,00 -3,38 -18.47% | -0,20 | -1,40 | -5,42 | -1,53 | 2,10 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 2,25 2,39 -5.78% | 0,59 0,02 3568.75% | 2,27 1,11 103.87% | -3,24 -0,15 -2132.01% | 2,53 -2,83 189.42% | 0,45 -0,07 776.23% | -2,68 -2,20 -21.86% | -11,9 -5,02 -136.89% | -7,06 -4,70 -50.15% | -3,17 | -4,14 | -8,16 | -4,27 | -0,64 |
|
Net income Million USD | Released Forecast Spread | 2,25 2,39 -5.78% | 116 0,02 722387.5% | 1,56 1,01 55.06% | -1,16 -0,13 -762.69% | 0,46 -2,30 120.02% | -0,31 -0,07 -333.68% | -2,09 -1,73 -21.18% | -9,51 -4,03 -135.98% | -6,01 -3,72 -61.66% | -2,46 | -3,20 | -6,32 | -3,31 | -0,51 |
|
EPS USD | Released Forecast Spread | 0,04 0,04 0% | 1,65 0,00 49649.55% | 0,02 0,01 50.04% | -0,02 -0,01 -300% | 0,01 -0,04 128.57% | 0,00 0,00 - | -0,03 -0,02 -28.59% | -0,15 -0,06 -140% | -0,09 -0,06 -56.52% | -0,04 | -0,05 | -0,10 | -0,06 | -0,01 |
| Announcement Date | 08/03/22 | 29/06/22 | 06/09/22 | 06/12/22 | 13/03/23 | 21/06/23 | 07/09/23 | 07/12/23 | 06/03/24 | - | - | - | - | - |
| 11/07/2024 07:00 | BONESUPPORT HOLDING AB: Q2 2024 Earnings Release |
| 15/07/2024 | SWEDISH ORPHAN BIOVITRUM AB: Q2 2024 Earnings Release |
| 22/07/2024 | BIOGEN INC.: Q2 2024 Earnings Release (Projected) |
| 23/07/2024 07:00 | BIOGAIA AB: Q2 2024 Earnings Release |
| 23/07/2024 | SAMSUNG BIOLOGICS CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 24/07/2024 | PHARMA MAR, S.A.: Q2 2024 Earnings Release (Projected) |
| 24/07/2024 | GRIFOLS, S.A.: Q2 2024 Earnings Release (Projected) |
| 25/07/2024 06:00 | UCB: Q2 2024 Earnings Release |
| 25/07/2024 | SK BIOSCIENCE CO.,LTD.: Q2 2024 Earnings Release (Projected) |
| 29/07/2024 | BIOMARIN PHARMACEUTICAL INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Peregrine Pharmaceuticals
| 23/05/2024 10:43 | CONCORD BIOTECH LIMITED: Q4 2024 Earnings Release |
| 14/05/2024 16:35 | GRIFOLS, S.A.: Q1 2024 Earnings Release |
| 13/05/2024 | NATURECELL CO.,LTD.: Q1 2024 Earnings Release |
| 09/05/2024 | PHARMARESEARCH CO., LTD.: Q1 2024 Earnings Release |
| 09/05/2024 | MEDY-TOX INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release |
| 09/05/2024 07:30 | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
| 08/05/2024 | HUGEL, INC.: Q1 2024 Earnings Release |
| 08/05/2024 21:16 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
